Skip to content
Study details
Enrolling now

Study of Tirzepatide for Recovery and Alcohol Use Management

Brigham and Women's Hospital
NCT IDNCT06727331ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

20

Study length

about 11 months

Ages

18+

Locations

2 sites in MA

What this study is about

This trial is testing whether tirzepatide helps people with alcohol use disorder (AUD) manage cravings. Participants will receive either tirzepatide or a placebo weekly for 319 days. The goal is to see if tirzepatide affects how people react to cues related to drinking.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Saline Placebo
  • 2.Take Tirzepatide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

tirzepatide

Drug routes

injection (Injection)

Endpoints

Primary: Incidence and Severity of Adverse Events

Secondary: Blood pressure, Columbia Suicide Severity Rating Scale (C-SSRS), Generalized Anxiety Disorder-7 (GAD-7), Heart rate, Hemoglobin A1c, Patient Health Questionnaire-8 (PHQ-8), Weight

Body systems

Psychiatry / Mental Health